{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,6,19]],"date-time":"2024-06-19T23:35:51Z","timestamp":1718840151384},"reference-count":24,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,8,4]]},"DOI":"10.7759\/cureus.27691","type":"journal-article","created":{"date-parts":[[2022,8,5]],"date-time":"2022-08-05T04:38:54Z","timestamp":1659674334000},"source":"Crossref","is-referenced-by-count":2,"title":["A Systematic Review on the Efficacy and Safety of Selective Serotonin Reuptake Inhibitors in Gastrointestinal Motility Disorders: More Control, Less Risk"],"prefix":"10.7759","author":[{"given":"Maitri V","family":"Acharekar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara E","family":"Guerrero Saldivia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sumedha","family":"Unnikrishnan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yeny Y","family":"Chavarria","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adebisi O","family":"Akindele","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana P","family":"Jalkh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aziza K","family":"Eastmond","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chaitra","family":"Shetty","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Syed Muhammad Hannan A","family":"Rizvi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joudi","family":"Sharaf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kerry-Ann D","family":"Williams","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maha","family":"Tariq","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prachi","family":"Balani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v20.i22.6759","article-title":"Irritable bowel syndrome: pathogenesis, diagnosis, treatment, and evidence-based medicine","volume":"20","author":"Saha L","year":"2014","unstructured":"Saha L. Irritable bowel syndrome: pathogenesis, diagnosis, treatment, and evidence-based medicine. World J Gastroenterol. 2014, 20:6759-73. 10.3748\/wjg.v20.i22.6759","journal-title":"World J Gastroenterol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.5507\/bp.2017.057","article-title":"Irritable bowel syndrome - from etiopathogenesis to therapy","volume":"162","author":"Radovanovic-Dinic B","year":"2018","unstructured":"Radovanovic-Dinic B, Tesic-Rajkovic S, Grgov S, Petrovic G, Zivkovic V. Irritable bowel syndrome - from etiopathogenesis to therapy. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2018, 162:1-9. 10.5507\/bp.2017.057","journal-title":"Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1159\/000505287","article-title":"Irritable bowel syndrome subtypes: new names for old medical conditions","volume":"38","author":"Grad S","year":"2020","unstructured":"Grad S, Dumitrascu DL. Irritable bowel syndrome subtypes: new names for old medical conditions. Dig Dis. 2020, 38:122-7. 10.1159\/000505287","journal-title":"Dig Dis"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.23736\/S0031-0808.18.03541-3","article-title":"Irritable bowel syndrome: the clinical approach","volume":"60","author":"Adriani A","year":"2018","unstructured":"Adriani A, Ribaldone DG, Astegiano M, Durazzo M, Saracco GM, Pellicano R. Irritable bowel syndrome: the clinical approach. Panminerva Med. 2018, 60:213-22. 10.23736\/S0031-0808.18.03541-3","journal-title":"Panminerva Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1038\/s41395-018-0222-5","article-title":"Effect of antidepressants and psychological therapies in irritable bowel syndrome: an updated systematic review and meta-analysis","volume":"114","author":"Ford AC","year":"2019","unstructured":"Ford AC, Lacy BE, Harris LA, Quigley EM, Moayyedi P. Effect of antidepressants and psychological therapies in irritable bowel syndrome: an updated systematic review and meta-analysis. Am J Gastroenterol. 2019, 114:21-39. 10.1038\/s41395-018-0222-5","journal-title":"Am J Gastroenterol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.25518","article-title":"Neurotransmitters: the critical modulators regulating gut-brain axis","volume":"232","author":"Mittal R","year":"2017","unstructured":"Mittal R, Debs LH, Patel AP, et al.. Neurotransmitters: the critical modulators regulating gut-brain axis. J Cell Physiol. 2017, 232:2359-72. 10.1002\/jcp.25518","journal-title":"J Cell Physiol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3390\/molecules27051680","article-title":"The role of serotonin neurotransmission in gastrointestinal tract and pharmacotherapy","volume":"27","author":"Guzel T","year":"2022","unstructured":"Guzel T, Mirowska-Guzel D. The role of serotonin neurotransmission in gastrointestinal tract and pharmacotherapy. Molecules. 2022, 27:1680. 10.3390\/molecules27051680","journal-title":"Molecules"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2018.04.032","article-title":"Management options for irritable bowel syndrome","volume":"93","author":"Camilleri M","year":"2018","unstructured":"Camilleri M. Management options for irritable bowel syndrome. Mayo Clin Proc. 2018, 93:1858-72. 10.1016\/j.mayocp.2018.04.032","journal-title":"Mayo Clin Proc"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000015920","article-title":"Pharmacological treatments for patients with irritable bowel syndrome: an umbrella review of systematic reviews and meta-analyses","volume":"98","author":"Qin D","year":"2019","unstructured":"Qin D, Yue L, Xue B, Chen M, Tang TC, Zheng H. Pharmacological treatments for patients with irritable bowel syndrome: an umbrella review of systematic reviews and meta-analyses. Medicine (Baltimore). 2019, 98:e15920. 10.1097\/MD.0000000000015920","journal-title":"Medicine (Baltimore)"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0127815","article-title":"Efficacy and safety of antidepressants for the treatment of irritable bowel syndrome: a meta-analysis","volume":"10","author":"Xie C","year":"2015","unstructured":"Xie C, Tang Y, Wang Y, Yu T, Wang Y, Jiang L, Lin L. Efficacy and safety of antidepressants for the treatment of irritable bowel syndrome: a meta-analysis. PLoS One. 2015, 10:e0127815. 10.1371\/journal.pone.0127815","journal-title":"PLoS One"},{"key":"ref11","article-title":"Irritable bowel syndrome: a disease still searching for pathogenesis, diagnosis and therapy","volume":"20","author":"Bellini M","year":"2014","unstructured":"Bellini M, Gambaccini D, Stasi C, Urbano MT, Marchi S, Usai-Satta P. Irritable bowel syndrome: a disease still searching for pathogenesis, diagnosis and therapy. World J Gastroenterol. 2014, 20:8807-20.","journal-title":"World J Gastroenterol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al.. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021, 372:n71. 10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2015.04.020","article-title":"Effect of amitriptyline and escitalopram on functional dyspepsia: a multicenter, randomized controlled study","volume":"149","author":"Talley NJ","year":"2015","unstructured":"Talley NJ, Locke GR, Saito YA, et al.. Effect of amitriptyline and escitalopram on functional dyspepsia: a multicenter, randomized controlled study. Gastroenterology. 2015, 149:340-9. 10.1053\/j.gastro.2015.04.020","journal-title":"Gastroenterology"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpsychores.2020.110351","article-title":"Symptom-network dynamics in irritable bowel syndrome with comorbid panic disorder using electronic momentary assessment: a randomized controlled trial of escitalopram vs. placebo","volume":"141","author":"Kreiter D","year":"2021","unstructured":"Kreiter D, Drukker M, Mujagic Z, et al.. Symptom-network dynamics in irritable bowel syndrome with comorbid panic disorder using electronic momentary assessment: a randomized controlled trial of escitalopram vs. placebo. J Psychosom Res. 2021, 141:110351. 10.1016\/j.jpsychores.2020.110351","journal-title":"J Psychosom Res"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(19)30324-3","article-title":"Efficacy of soluble fibre, antispasmodic drugs, and gut-brain neuromodulators in irritable bowel syndrome: a systematic review and network meta-analysis","volume":"5","author":"Black CJ","year":"2020","unstructured":"Black CJ, Yuan Y, Selinger CP, Camilleri M, Quigley EMM, Moayyedi P, Ford AC. Efficacy of soluble fibre, antispasmodic drugs, and gut-brain neuromodulators in irritable bowel syndrome: a systematic review and network meta-analysis. Lancet Gastroenterol Hepatol. 2020, 5:117-31. 10.1016\/S2468-1253(19)30324-3","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpain.2018.01.007","article-title":"Research design characteristics of published pharmacologic randomized clinical trials for irritable bowel syndrome and chronic pelvic pain conditions: an ACTTION systematic review","volume":"19","author":"Gewandter JS","year":"2018","unstructured":"Gewandter JS, Chaudari J, Iwan KB, et al.. Research design characteristics of published pharmacologic randomized clinical trials for irritable bowel syndrome and chronic pelvic pain conditions: an ACTTION systematic review. J Pain. 2018, 19:717-26. 10.1016\/j.jpain.2018.01.007","journal-title":"J Pain"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1590\/S0004-2803.202100000-20","article-title":"Interventions for the treatment of irritable bowel syndrome: a review of cochrane systematic reviews","volume":"58","author":"Scaciota AC","year":"2021","unstructured":"Scaciota AC, Matos D, Rosa MM, Colovati ME, Bellotto EF, Martimbianco AL. Interventions for the treatment of irritable bowel syndrome: a review of cochrane systematic reviews. Arq Gastroenterol. 2021, 58:120-6. 10.1590\/S0004-2803.202100000-20","journal-title":"Arq Gastroenterol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1007\/s10354-017-0592-0","article-title":"Intestinal microbiome-gut-brain axis and irritable bowel syndrome","volume":"168","author":"Moser G","year":"2018","unstructured":"Moser G, Fournier C, Peter J. Intestinal microbiome-gut-brain axis and irritable bowel syndrome. Wien Med Wochenschr. 2018, 168:62-6. 10.1007\/s10354-017-0592-0","journal-title":"Wien Med Wochenschr"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.3390\/ijms221910235","article-title":"Enteric microbiota-mediated serotonergic signaling in pathogenesis of irritable bowel syndrome","volume":"22","author":"Mishima Y","year":"2021","unstructured":"Mishima Y, Ishihara S. Enteric microbiota-mediated serotonergic signaling in pathogenesis of irritable bowel syndrome. Int J Mol Sci. 2021, 22:10235. 10.3390\/ijms221910235","journal-title":"Int J Mol Sci"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.3390\/nu13093061","article-title":"Irritable bowel syndrome, depression, and neurodegeneration: a bidirectional communication from gut to brain","volume":"31","author":"Aziz MNM","year":"2021","unstructured":"Aziz MNM, Kumar J, Muhammad Nawawi KN, Raja Ali RA, Mokhtar NM. Irritable bowel syndrome, depression, and neurodegeneration: a bidirectional communication from gut to brain. Nutrients. 2021, 31:3061. 10.3390\/nu13093061","journal-title":"Nutrients"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-022-03365-z","article-title":"Irritable bowel syndrome and microbiome; switching from conventional diagnosis and therapies to personalized interventions","volume":"20","author":"Ghaffari P","year":"2022","unstructured":"Ghaffari P, Shoaie S, Nielsen LK. Irritable bowel syndrome and microbiome; switching from conventional diagnosis and therapies to personalized interventions. J Transl Med. 2022, 20:173. 10.1186\/s12967-022-03365-z","journal-title":"J Transl Med"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1038\/nrgastro.2013.105","article-title":"Serotonin signalling in the gut-functions, dysfunctions and therapeutic targets","volume":"10","author":"Mawe GM","year":"2013","unstructured":"Mawe GM, Hoffman JM. Serotonin signalling in the gut-functions, dysfunctions and therapeutic targets. Nat Rev Gastroenterol Hepatol. 2013, 10:473-86. 10.1038\/nrgastro.2013.105","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1007\/s11894-018-0664-3","article-title":"Psychotropics, antidepressants, and visceral analgesics in functional gastrointestinal disorders","volume":"20","author":"T\u00f6rnblom H","year":"2018","unstructured":"T\u00f6rnblom H, Drossman DA. Psychotropics, antidepressants, and visceral analgesics in functional gastrointestinal disorders. Curr Gastroenterol Rep. 2018, 20:58. 10.1007\/s11894-018-0664-3","journal-title":"Curr Gastroenterol Rep"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v20.i27.8796","article-title":"Irritable bowel syndrome: a concise review of current treatment concepts","volume":"20","author":"Wall GC","year":"2014","unstructured":"Wall GC, Bryant GA, Bottenberg MM, Maki ED, Miesner AR. Irritable bowel syndrome: a concise review of current treatment concepts. World J Gastroenterol. 2014, 20:8796-806. 10.3748\/wjg.v20.i27.8796","journal-title":"World J Gastroenterol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/102631-a-systematic-review-on-the-efficacy-and-safety-of-selective-serotonin-reuptake-inhibitors-in-gastrointestinal-motility-disorders-more-control-less-risk","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:37:59Z","timestamp":1707507479000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/102631-a-systematic-review-on-the-efficacy-and-safety-of-selective-serotonin-reuptake-inhibitors-in-gastrointestinal-motility-disorders-more-control-less-risk"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,4]]},"references-count":24,"URL":"https:\/\/doi.org\/10.7759\/cureus.27691","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8,4]]}}}